Samsung Biologics Co Ltd (207940)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Samsung Biologics Co Ltd (207940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013458
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities includes process development, contract manufacturing, aseptic fill and finish and project management. Its cell culture development process includes upstream, downstream and analytical technology. Samsung Biologics’ provides manufacturing and quality assurance for the clinical and commercial products. The company also provides infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products. It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.

Samsung Biologics Co Ltd (207940) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MilliporeSigma to Enter into Agreement with Samsung Biologics 10
AstraZeneca Forms Joint Venture with Samsung Biologics 11
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 12
Equity Offering 13
Samsung Biologics Raises USD2.03 Billion in IPO 13
Samsung Biologics Co Ltd – Key Competitors 14
Samsung Biologics Co Ltd – Key Employees 15
Samsung Biologics Co Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Joint Venture 16
Recent Developments 17
Financial Announcements 17
Apr 25, 2017: Samsung BioLogics announces its financial results for 1Q 2017 17
Jan 24, 2017: Samsung BioLogics sales and profits in 2016 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Samsung Biologics Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MilliporeSigma to Enter into Agreement with Samsung Biologics 10
AstraZeneca Forms Joint Venture with Samsung Biologics 11
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 12
Samsung Biologics Raises USD2.03 Billion in IPO 13
Samsung Biologics Co Ltd, Key Competitors 14
Samsung Biologics Co Ltd, Key Employees 15
Samsung Biologics Co Ltd, Joint Venture 16

★海外企業調査レポート[Samsung Biologics Co Ltd (207940)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BlackBerry Ltd:企業のM&A・事業提携・投資動向
    BlackBerry Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BlackBerry Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Paradigm Biopharmaceuticals Ltd (PAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Paradigm Biopharmaceuticals Ltd (Paradigm Biopharma) is a biopharmaceutical company. The company focused on research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma …
  • Steppe Cement Ltd:企業の戦略・SWOT・財務情報
    Steppe Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary Steppe Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Main Street America Group Inc:企業の戦略的SWOT分析
    Main Street America Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Max-Delbruck-Centrum fur Molekulare Medizin (MDC)-製薬・医療分野:企業M&A・提携分析
    Summary Max-Delbruck-Centrum fur Molekulare Medizin (MDC) is a biomedical research centre. The centre offers molecular biology research services, signal transduction research, development biology research, molecular immunology and gene therapy research, non coding RNAs research, cytoplasmic gene reg …
  • Shionogi Inc:企業の戦略的SWOT分析
    Shionogi Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Chang Hwa Commercial Bank, Ltd.:企業の戦略・SWOT・財務分析
    Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Carisma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carisma Therapeutics Inc (Carisma Therapeutics), formerly CARMA Therapeutics LLC, is a biotechnology company with focus on the discovery and development of macrophage-based immunotherapeutics for the treatment of cancer. The company exploits its proprietary CAR-macrophage platform to provide …
  • QuickLogic Corporation (QUIK):企業の財務・戦略的SWOT分析
    QuickLogic Corporation (QUIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • IMPACT Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary IMPACT Therapeutics Inc (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; …
  • Birchcliff Energy Ltd (BIR)-石油・ガス分野:企業M&A・提携分析
    Summary Birchcliff Energy Ltd. (Birchcliff) is an intermediate oil and gas company that explores for, develops and produces natural gas, light oil and natural gas liquids. It operates in the Peace River Arch area to the northwest of Grande Prairie, Alberta. Peach River Arch region is one of the pote …
  • Qurate Retail Inc (QRTEA):企業の財務・戦略的SWOT分析
    Qurate Retail Inc (QRTEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Itausa – Investimentos Itau SA (ITSA4):企業の財務・戦略的SWOT分析
    Itausa - Investimentos Itau SA (ITSA4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • FibroGen Inc (FGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney d …
  • Sino Oil and Gas Holdings Ltd (702):石油・ガス:M&Aディール及び事業提携情報
    Summary Sino Oil and Gas Holdings Ltd (Sino Oil and Gas), formerly Genesis Energy Holdings Ltd, is an oil and gas company that offers production and development of oil properties. The company offers services such as oil and gas exploration, production, distribution, development and supplying service …
  • Aduro BioTech Inc (ADRO):企業の財務・戦略的SWOT分析
    Aduro BioTech Inc (ADRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aequus Pharmaceuticals Inc (AQS):医療機器:M&Aディール及び事業提携情報
    Summary Aequus Pharmaceuticals Inc (Aequus Pharmaceuticals) is a drug discovery and development company that develops differentiated drugs. The company’s pipeline products include AQS301, AQS302 and AQS303. Its commercial pipeline comprises ophthalmology products and transplant products. Aequus Phar …
  • SKYCITY Entertainment Group Ltd:戦略・SWOT・企業財務分析
    SKYCITY Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary SKYCITY Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mymetics Corp (MYMX)-製薬・医療分野:企業M&A・提携分析
    Summary Mymetics Corp (Mymetics) is a biotechnology company that develops next-generation prophylactic vaccines for infectious diseases. The company's product pipeline includes vaccine candidates that target HIV-1/AIDS, chikungunya, intranasal influenza, malaria, herpes simplex virus (HSV) and respi …
  • Quest Diagnostics Incorporated:企業の戦略・SWOT・財務情報
    Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report Summary Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆